Literature DB >> 16097719

Bipolar disorder--costs and comorbidity.

Robert M A Hirschfeld1, Lana A Vornik.   

Abstract

Not only is bipolar disorder a chronic, severe psychiatric disorder, it is also expensive to treat and expensive to society. An estimate of the total cost of bipolar disorder made more than a decade ago was as high as 45 billion dollars per year. Most of this cost is accounted for by indirect costs related to reduced functional capacity and lost work. Patients with bipolar disorder have higher rates of utilization of healthcare resources compared with the general population and compared with patients with other types of psychiatric conditions. Comorbidity contributes to the heavy burden that bipolar disorder imposes on society. Bipolar disorder frequently occurs together with other psychiatric disorders, especially anxiety disorders and substance abuse. In addition, bipolar disorder has been associated with a variety of general medical conditions, which further complicate management of the psychiatric disorder.

Entities:  

Mesh:

Year:  2005        PMID: 16097719

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  21 in total

1.  Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey.

Authors:  John A Bates; Richard Whitehead; Susan C Bolge; Edward Kim
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

3.  A linkage and family-based association analysis of a potential neurocognitive endophenotype of bipolar disorder.

Authors:  Jonathan Savitz; Lize van der Merwe; Mark Solms; Rajkumar Ramesar
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  Evaluation of tissue collection for postmortem studies of bipolar disorder.

Authors:  Amy Deep-Soboslay; Bianca Iglesias; Thomas M Hyde; Llewelyn B Bigelow; Vesna Imamovic; Mary M Herman; Joel E Kleinman
Journal:  Bipolar Disord       Date:  2008-11       Impact factor: 6.744

Review 5.  Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

6.  Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder.

Authors:  Louisa G Sylvia; Andrew A Nierenberg; Jonathan P Stange; Andrew D Peckham; Thilo Deckersbach
Journal:  J Psychiatr Pract       Date:  2011-05       Impact factor: 1.325

7.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

8.  Abnormal amygdala-prefrontal effective connectivity to happy faces differentiates bipolar from major depression.

Authors:  Jorge Renner Cardoso de Almeida; Amelia Versace; Andrea Mechelli; Stefanie Hassel; Karina Quevedo; David Jerome Kupfer; Mary Louise Phillips
Journal:  Biol Psychiatry       Date:  2009-05-17       Impact factor: 13.382

9.  Identification and individualized prediction of clinical phenotypes in bipolar disorders using neurocognitive data, neuroimaging scans and machine learning.

Authors:  Mon-Ju Wu; Benson Mwangi; Isabelle E Bauer; Ives C Passos; Marsal Sanches; Giovana B Zunta-Soares; Thomas D Meyer; Khader M Hasan; Jair C Soares
Journal:  Neuroimage       Date:  2016-02-13       Impact factor: 6.556

10.  Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Authors:  Monali Bhosle; Joshua S Benner; Mitch Dekoven; Jeff Shelton
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.